Lamb Weston Holdings Inc (LW) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...

Q & A Highlights

Q : What is Lamb Weston's view on its structural or normalized EBITDA margin given the current capacity utilization projections? A : Thomas Werner, President and CEO, stated that assuming all announced capacity comes online, the go-forward EBITDA margin is expected to be in the range of 19% to 20%. Bernadette Madarieta, CFO, added that they plan to expand margins by pricing to offset inflation over the longer term, but in the short- to medium-term, they expect 19% to 20% EBITDA margins.

Q : Why haven't other industry players made similar decisions to curtail production or close less efficient facilities? A : Thomas Werner explained that Lamb Weston is managing its business based on the current environment and anticipates that other industry players may take actions, but it remains to be seen. Bernadette Madarieta added that they expect the industry to be generally balanced in the long term, based on continued category growth and positive French fry attachment rates.

Q : Can you elaborate on the pressures in the international business, particularly in Europe and Asia? A : Thomas Werner noted that in Europe, the initial high-cost potato crop and competitive market have made it difficult to pass inflation costs to customers. In Asia, the market is more competitive than anticipated, partly due to ERP challenges that affected customer relationships. Bernadette Madarieta added that increased capacity in Asia has turned it into more of an export market.

Q : How aggressive will Lamb Weston be with its expanded share buyback program? A : Bernadette Madarieta stated that with increased free cash flow expected in the second half of the year, Lamb Weston plans to opportunistically buy back shares. The increased authorization of $250 million provides flexibility for share repurchases.

Q : What are the reasons for weak consumer demand, and is there any impact from GLP-1 weight loss drugs? A : Bernadette Madarieta explained that in the US, demand decline is primarily due to inflation and reduced restaurant traffic, with consumers trading down to smaller servings. Internationally, restaurant traffic has slowed due to price inflation. They have not seen a significant impact from GLP-1 drugs on demand.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .

This article first appeared on GuruFocus .